JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy
  • Search
  • Contact Us
  • Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs

  • Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity

  • FDA Approves Lilly's Tirzepatide for Obesity

  • GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease

  • Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach

  • Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease

  • The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity

  • Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research

  • Understanding and Addressing the Stigma Faced by People with Type 2 Diabetes and Obesity

  • Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss

  • You are here:  
  • Home
  • Tags
  • Obesity
 

JCS/T2D

We are advocates. We learn. We share. We inform.
Bringing clarity to type 2 diabetes, obesity care, health research, and the data behind them.

Content is provided for educational and informational purposes and is not medical advice.

Helpful Links

About Us
Contact Us
JCS Analytics

Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.